Pyoderma gangrenosum
Pyoderma gangrenosum د پوستکي یوه نادره، التهابي ناروغي ده چیرې چې دردناک پسټول یا نوډولونه په زخمونو بدلیږي چې په تدریجي ډول وده کوي. Pyoderma gangrenosum ساري نه ده. په درملنه کې کیدای شي کورټیکوسټرایډونه، سیکلوسپورین، یا مختلف مونوکلونل انټي باډي شامل وي. که څه هم دا کولی شي د هر عمر په خلکو اغیزه وکړي، دا اکثرا د 40 او 50 کلونو په خلکو اغیزه کوي.
☆ د آلمان څخه د 2022 سټیفټنګ وارینسټ پایلو کې ، د ماډلډرم سره د مصرف کونکي رضایت د تادیه شوي ټیلی میډیسن مشورې په پرتله یوازې یو څه ټیټ و.
د هغه چا په پښه کې چې د کولمو السریت لري.
References
Pyoderma gangrenosum د پوستکي یو نادر حالت دی چې د سور یا ارغواني څنډو سره د دردناک زخمونو لامل کیږي. دا د التهابي ناروغۍ په توګه طبقه بندي شوې او د یوې ډلې برخه ده چې د نیوټروفیلیک ډرماتوز په نوم یادیږي. د pyoderma gangrenosum لامل پیچلی دی، په هغو خلکو کې چې د جنیتي پلوه زیانمن شوي دي، د طبیعي او تطبیقي معافیت سره ستونزې لري. په دې وروستیو کې، څیړونکو د ویښتو follicule باندې د ناروغۍ د احتمالي پیل ټکي په توګه تمرکز کړی.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum د پوستکي یو نادر حالت دی چې خورا دردناک زخمونه رامینځته کوي. پداسې حال کې چې موږ د دې لامل په بشپړ ډول نه پوهیږو، موږ پوهیږو چې پدې کې د ځینې معافیت حجرو فعالیت زیاتیږي. د ناروغۍ درملنه لاهم اسانه نه ده. موږ مختلف درمل لرو چې د معافیت سیسټم فشاروي یا د هغې فعالیت بدلوي. د دې ترڅنګ، موږ د زخمونو درملنه او د درد اداره کولو باندې هم تمرکز کوو. Corticosteroids او cyclosporine اکثرا د درملنې لپاره لومړی انتخاب دی، مګر پدې وروستیو کې، د بیولوژیکي درملنې لکه TNF-α مخنیوی کونکو کارولو په اړه ډیرې څیړنې شوي. دا بیولوژیکي په زیاتیدونکي توګه غوره کیږي، په ځانګړې توګه په ناروغانو کې چې د نورو التهابي شرایطو سره، او دوی د ناروغۍ په بهیر کې مخکې کارول کیږي.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
